VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2022

Jul 27, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2022-07-25

Reporting Person: LEIDEN JEFFREY M (Director, Executive Chairman)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-07-25	Common Stock	M	60342	$91.05	Acquired	134502	Direct
2022-07-25	Common Stock	S	13869	$279.44	Disposed	120633	Direct
2022-07-25	Common Stock	S	32983	$280.37	Disposed	87650	Direct
2022-07-25	Common Stock	S	34090	$281.27	Disposed	53560	Direct
2022-07-25	Common Stock	S	40666	$282.43	Disposed	12894	Direct
2022-07-25	Common Stock	S	10471	$283.42	Disposed	2423	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-07-25	Stock Option (Right to Buy)	$91.05	M	60342	Disposed	2026-02-01	Common Stock (60342)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	440	Indirect

Footnotes

F1: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1.

F2: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F3: Open market sales reported on this line occurred at a weighted average price of $279.44 (range $278.90 to $279.89).

F4: Open market sales reported on this line occurred at a weighted average price of $280.37 (range $279.90 to $280.88).

F5: Open market sales reported on this line occurred at a weighted average price of $281.27 (range $280.90 to $281.89).

F6: Open market sales reported on this line occurred at a weighted average price of $282.43 (range $281.90 to $282.89).

F7: Open market sales reported on this line occurred at a weighted average price of $283.42 (range $282.90 to $283.84).

F8: Fully vested.